ONMD
OneMedNet Corporation
There isn't enough reported data to score ONMD yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ONMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
ONMD's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ONMD PE Valuation
ONMD has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ONMD Forward outlook
There aren't enough analyst estimates for ONMD to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ONMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.50 | -$0.20 |
| Q1 2026 | -$0.40 | +$3.10 |
| Q4 2025 | -$0.60 | +$3.20 |
| Q3 2025 | -$0.70 | +$48.80 |
| Q2 2025 | -$1.30 | +$48.70 |
ONMD is still losing money, but far less than before: $1.50 per share over the past year, against $50.00 at its worst in mid-2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ONMD on earnings quality, reporting a profit while its opponent remains loss making.
ONMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $292K | +88% |
| Q1 2026 | $96K | -30% |
| Q4 2025 | $891K | +3327% |
| Q3 2025 | $177K | +25% |
| Q2 2025 | $155K | -32% |
| Q1 2025 | $137K | -45% |
| Q4 2024 | $26K | -92% |
ONMD's revenue is growing: $292,000 last quarter, up 88% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -774% | +557 points |
| Q1 2026 | -2658% | -1035 points |
| Q4 2025 | -346% | +9908 points |
| Q3 2025 | -1263% | +418 points |
| Q2 2025 | -1331% | -250 points |
| Q1 2025 | -1623% | -776 points |
| Q4 2024 | -10254% | -8697 points |
| Q3 2024 | -1681% | N/A |
ONMD's operating margin was −774% last quarter, up 557 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ONMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ONMD on profitability, with a higher operating margin.
ONMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.9M | +$403K |
| Q1 2026 | -$1.5M | +$409K |
| Q4 2025 | -$1.7M | +$344K |
| Q3 2025 | -$1.6M | +$354K |
| Q2 2025 | -$2.3M | -$780K |
| Q1 2025 | -$2M | -$400K |
| Q4 2024 | -$2.1M | +$1.9M |
| Q3 2024 | -$1.9M | -$1.8M |
ONMD has burned cash in almost every quarter: −$7M over the past year, against −$8M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ONMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
ONMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +270K shares |
| 1 year | +51% | +2M shares |
| 3 years | +288% | +4.3M shares |
ONMD has 6M diluted shares, up 51% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over ONMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ONMD Net Leverage
ONMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ONMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 29.2 | Neutral |
ONMD's weekly RSI is 45 (neutral) and its Stochastic is 29 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ONMD PE vs Healthcare Sector
ONMD has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ONMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.01 | 6.8% above |
| 20 week MA | $6.04 | 11% below |
| 50 week MA | $7.98 | 33% below |
| 100 week MA | $8.66 | 38% below |
| 200 week MA | $29.9 | 82% below |
ONMD has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 82% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ONMD on trend strength, trading above more of its moving averages.
ONMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $99.4 | $101.0 | +1.6% |
| 2022 | $101.0 | $104.4 | +3.4% |
| 2023 | $104.4 | $8.10 | -92% |
| 2024 | $8.10 | $13.3 | +64% |
| 2025 | $13.3 | $12.7 | -4.5% |
| 2026 YTD | $12.7 | $5.35 | -58% |
ONMD is down 58% so far in 2026, after finishing higher in three of the previous five years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ONMD on returns for 2026, with the stronger performance.